A non-innovator version of etanercept for treatment of arthritis

Biologicals

Volumn 39, Issue 6, 2011, Pages 384-395

  Maity, Sunit ^a   Ullanat, Rajesh ^a   Lahiri, Subhra ^a   Shekar, Sunil ^a   Sodhan, Geetha ^a   Vyas, Ashutosh ^a   Dyaga, Gopal ^a   Ireni, Srinivas ^a   Nair, Nirmala ^a   Sotsios, Yannis ^b   Maria, Denis C ^b   Morawala Patell Villoo, V ^a  

^a Avesthagen Limited   (India)

^b BioMedCode SA   (Greece)

Author keywords

Biosimilars; Recombinant protein

Indexed keywords

AVENT; AVG 01; ETANERCEPT; PLACEBO; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTHRITIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; EXPRESSION VECTOR; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; MOLECULAR CLONING; MOUSE; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; RAT; ULTRAVIOLET SPECTROSCOPY;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME;

EID: 80055051682     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.08.014     Document Type: Article

References (16)

1. Fuhr J. Biosimilars and follow-on biologics. Expert Rev Pharmacoeconomics Outcomes Res 2009, 9:149-150.
2. Schellekens H. Follow-on biologics: challenges of the 'next generation'. Nephrol Dial Transplant 2005, 20:iv31-iv36.
3. Roger S. Biosimilars: how similar or dissimilar are they?. Nephrology 2006, 11:341-346.
4. Fleischmann R., Shealy D. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. Mol Invention 2003, 3:310-318.
5. Stoll J.G., Yasothan U. Rheumatoid arthritis market. Nat Rev Drug Discov 2009, 8:693-694.
6. Wong M., Ziring D., Korin Y., Desai S., Kim S., Lin J., et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008, 126:121-136.
7. Chapple S.D., Crofts A.M., Shadbolt S.P., McCafferty J., Dyson M.R. Multiplexed expression and screening for recombinant protein production in mammalian cells. BMC Biotechnol 2006, 6:49-63.
8. Yin J., Li G., Ren X., Herrler G. Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J Biotechnol 2007, 127:335-347.
9. Sharfstein S.T. Advances in cell culture process development: tools and techniques for improving cell line development and process optimization. Biotechnol Prog 2008, 24:727-734.
10. Morgan M.J., Faik P. Carbohydrate metabolism in cultured animal cells. Biosci Rep 1981, 1:669-686.
11. Hahn R., Schlegel R., Jungbauer A. Comparison of protein A affinity sorbents. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 790:35-51.
12. Hober S., Nord K., Linhult M. Protein A chromatography for antibody purification. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 848:40-47.
13. Malfait A.M., Williams R.O., Malik A.S., Maini R.N., Feldmann M. Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis Rheum 2001, 44:1215-1224.
14. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991, 10:4025-4031.
15. Li P., Schwarz E.M. The TNF-alpha transgenic mouse model of inflammatory arthritis. Springer Semin Immunopathol 2003, 25:19-33.
16. Douni E., Sfikakis P.P., Haralambous S., Fernandes P., Kollias G. Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther 2004, 6:R65-R72.